NBIX vs UHS: fair value comparison
Neurocrine Biosciences, Inc. and Universal Health Services, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NBIX currently sits closer to the top of our discount ranking. NBIX carries the stronger quality grade.
| NBIX | UHS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $166.23 | $171.66 |
| 12-month range | $131.78–$167.77 | $144.69–$239.43 |
| Sector rank | #18 of 113 Healthcare | #23 of 113 Healthcare |
| Quality grade | C+ | C |
| Momentum grade | — | A |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: NBIX fair value analysis · UHS fair value analysis